Business Wire

Mavenir Study Reveals Moving to Converged 5G Packet Core Can Reduce TCO by up to 36%

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, released an in-depth study, with Monica Paolini at Senza Fili, highlighting how accelerating the move to a Converged 5G Core (5GC) can reduce Total Cost of Ownership (TCO) by up to 36%.

The study concludes that Mobile Network Operators (MNOs) can save by moving to a cloud-native Converged 5GC with 5G Standalone (SA) support as they deploy their 5G access network, instead of relying on legacy EPC technologies and 5G Non-Standalone (NSA) packet core support. The longer the MNO delays the transition to a Converged 5GC, the higher the transition costs.

The basis of the research, a TCO comparative analysis, revealed that the cost incurred in postponing the adoption of a Converged 5G core increases the TCO over a five-year period. The model assumes that the MNO moves to a state-of-the-art cloud-native converged 5GC and SA solution that replaces a traditional Evolved Packet Core (EPC).

The research in this whitepaper answers one key question: When should an MNO with a 5G access network transition to a cloud-native Converged 5G Core with 5G Standalone (SA) support? The comparative analysis studies different approaches taken by MNOs, namely early adopters vs. late adopters. Eventually, in both scenarios, the MNO moves to the Converged 5GC, but the cost impact of delaying the adoption of Converged 5GC grows with time. The early adopter cost saving over the late adopter grows to 36% for a fifth-year switch.

Ashok Khuntia, GM, Packet Computing, Mavenir said, “This research reveals that delaying an essential network transition will only increase costs in the long run. As the ‘fastest growing software vendor for Converged 5G Core’1, Mavenir works closely with our customers to help them make the transition to open and intelligent networks. We do so by delivering a flexible, cost-effective journey to 5G with multi-generational support for all G’s to modernize existing mobile networks while evolving to 5G. In addition, the Mavenir Converged 5G Core also supports non-3GPP access and can be tailored to fit any customer infrastructure and business needs.”

Mavenir Converged 5G Packet Core with multi-access support (2G, 3G, 4G, 5G NSA, 5G SA, and non-3GPP) allows CSPs a strategic growth plan with minimal risk, unlimited scale, and greatly improved speed, security, and reliability. Moving to a Converged 5G Packet Core now enables new, innovative opportunities. Mavenir’s cloud-native packet core network architecture simplifies network transformation, enables operational efficiencies, and focuses on core principles that consistently result in customer success.

Download the report.

1LightCounting 3Q21 WIRELESS INFRASTRUCTURE Report

Mavenir’s Converged Packet Core Solution Brief

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mavenir Media Office:
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
PR@mavenir.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye